Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000921895-25-002023
Filing Date
2025-07-24
Accepted
2025-07-24 15:53:54
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 28697
2 TRANSACTION IN SECURITIES ex1to13da913392004_072425.htm EX-1 3085
3 TERMINATION OF COOPERATION AGREEMENT ex991to13da913392004_072425.htm EX-99.1 43732
4 TERMINATION OF GROUP AGREEMENT ex992to13da913392004_072425.htm EX-99.2 21768
  Complete submission text file 0000921895-25-002023.txt   99197
Mailing Address 9920 PACIFIC HEIGHTS BLVD SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD SUITE 150 SAN DIEGO CA 92121 858-369-7100
MEI Pharma, Inc. (Subject) CIK: 0001262104 (see all company filings)

EIN.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-79594 | Film No.: 251146798
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248
Business Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248 214.866.0202
Anson Funds Management LP (Filed by) CIK: 0001491072 (see all company filings)

EIN.: 300134498 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13D/A